Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.

Biotech Giants' SG&A Costs: A Decade of Divergence

__timestampAlnylam Pharmaceuticals, Inc.CymaBay Therapeutics, Inc.
Wednesday, January 1, 2014445260008185000
Thursday, January 1, 2015606100008871000
Friday, January 1, 2016893540009645000
Sunday, January 1, 201719936500012387000
Monday, January 1, 201838235900014381000
Tuesday, January 1, 201947900500019238000
Wednesday, January 1, 202058842000017425000
Friday, January 1, 202162063900023040000
Saturday, January 1, 202277065800025116000
Sunday, January 1, 202379564600051953000
Monday, January 1, 2024975526000
Loading chart...

Cracking the code

A Tale of Two Biotechs: Alnylam vs. CymaBay

In the dynamic world of biotechnology, managing operational costs is crucial for sustaining innovation and growth. Alnylam Pharmaceuticals, Inc. and CymaBay Therapeutics, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Alnylam's Selling, General, and Administrative (SG&A) expenses surged by over 1,600%, reflecting its aggressive expansion and investment in groundbreaking therapies. In contrast, CymaBay's SG&A expenses grew by approximately 535%, indicating a more measured approach.

Alnylam's expenses peaked in 2023, reaching nearly 800 million, a testament to its commitment to scaling operations. Meanwhile, CymaBay's expenses, though significantly lower, saw a notable increase in 2023, suggesting strategic shifts. This divergence highlights the varied strategies biotech firms employ to navigate the competitive landscape. As these companies continue to evolve, their financial strategies will remain pivotal in shaping their future trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025